Joseph Ruda, MD
Ophthalmology · Houston, TXNPI 1760466395
Payments from drug & device makers
Across 12 payments — averaging $32.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Notal Vision, Inc.$110
- Regeneron Healthcare Solutions, Inc.$95
- Novartis$43
- AbbVie$41
- SK Life Science, Inc.$33
- Bausch & Lomb, A Division Of Bausch Health US, LLC$27
- plus $36 from 2 others
What the payments were for
- Speaking & faculty fees$11029%
- Food & beverage$27571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Notal Vision, Inc. | 3 | $110 |
| Regeneron Healthcare Solutions, Inc. | 1 | $95 |
| Novartis | 2 | $43 |
| AbbVie | 2 | $41 |
| SK Life Science, Inc. | 1 | $33 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $27 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $14 |
How this compares
$385 in reported general payments places this provider in the 20th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Timolol Maleate | 58 | $2,300 |
| Levobunolol Hcl | 34 | $654 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 48 | $592 |
| Latanoprost | 67 | $503 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 15 | $417 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $332 |
| Dorzolamide Hcl | 13 | $147 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Houston
- David BrownHouston$51.7M
- John MichelettiHouston$3.3M
- Michael CaplanHouston$1.4M
- Shaheen KavoussiHouston$1.3M
- Kevin JongHouston$1.2M
- Stephen SladeHouston$1.2M
- Rosa TangHouston$1.1M
- Zaina Al-MohtasebHouston$1.1M
- Fiaz ZamanHouston$1M
- Stephen PflugfelderHouston$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.